Whittier Trust Co. Has $1.72 Million Stock Position in IQVIA Holdings Inc. $IQV

Whittier Trust Co. reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 40.0% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,062 shares of the medical research company’s stock after selling 6,721 shares during the quarter. Whittier Trust Co.’s holdings in IQVIA were worth $1,718,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA during the 4th quarter valued at $25,000. Ascentis Independent Advisors acquired a new stake in IQVIA in the first quarter worth $25,000. International Assets Investment Management LLC bought a new stake in IQVIA in the fourth quarter valued at $27,000. Gilpin Wealth Management LLC acquired a new position in shares of IQVIA during the fourth quarter valued at about $27,000. Finally, CrossGen Wealth LLC bought a new position in shares of IQVIA during the 4th quarter worth about $28,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on IQV shares. Robert W. Baird boosted their target price on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research report on Wednesday, July 1st. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. HSBC reissued a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research note on Monday. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $223.88.

IQVIA Trading Up 1.2%

Shares of IQV stock opened at $208.43 on Wednesday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The company has a market capitalization of $34.79 billion, a price-to-earnings ratio of 25.83, a PEG ratio of 1.77 and a beta of 1.20. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $247.04. The company has a 50-day simple moving average of $178.78 and a two-hundred day simple moving average of $188.85.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board of directors believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.